| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453751 | Lung Cancer | 2018 | 6 Pages |
Abstract
The status of acquired T790M mutation was correlated with exon 19 deletion and longer progression-free survival to first- or second-generation EGFR-TKIs. A third-generation EGFR-TKI, osimertinib, was strongly associated with brain metastasis-free survival as well as other survival indicators in patients with EGFR-mutant lung adenocarcinoma.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jin Woo Joo, Min Hee Hong, Hyo Sup Shim,